Distribution of the LDL receptor within clathrin-coated pits and caveolae in rat and human liver

•The LDL receptor could be located at once in clathrin-coated pits and caveolae.•Treatments can shift the distribution of the LDL receptor at the plasma membrane.•Distribution of the receptor to caveolae matched a reduction in LDL internalization. Several findings suggest that the low-density lipopr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemical and biophysical research communications 2014-03, Vol.445 (2), p.422-427
Hauptverfasser: Ivaturi, Soumya, Wooten, Catherine J., Nguyen, Maikhanh D., Ness, Gene C., Lopez, Dayami
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•The LDL receptor could be located at once in clathrin-coated pits and caveolae.•Treatments can shift the distribution of the LDL receptor at the plasma membrane.•Distribution of the receptor to caveolae matched a reduction in LDL internalization. Several findings suggest that the low-density lipoprotein (LDL) receptor may internalize different lipoprotein particles via diverse pathways. Using a combination of discontinuous sucrose gradients and Triton solubilization studies, we demonstrated that the LDL receptor could be located simultaneously in clathrin-coated pits and caveolae in rat and human liver and in human hepatocyte-like C3A cells. Treatment with the cholesterol biosynthesis inhibitor, zaragozic acid A, shifted the distribution of the LDL receptor to clathrin containing fractions, whereas treatment with cholesterol or LDL shifted the receptor distribution towards caveolin-1 containing fractions. The LDL-dependent shift of the LDL receptor to caveolae coincided with a reduction in internalization of Bodipy-LDL. Redistribution within plasma membrane microdomains in response to specific treatments resulting in changes in LDL receptor function represents a novel paradigm that could be exploited in the development of a new class of therapeutic drugs.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2014.02.019